TY - JOUR
T1 - Determination of the cutoff values of Th2 markers for the prediction of future exacerbation in severe asthma
T2 - An analysis from the Hokkaido Severe Asthma Cohort Study
AU - The Hi-CARAT investigators
AU - Kimura, Hirokazu
AU - Makita, Hironi
AU - Taniguchi, Natsuko
AU - Takei, Nozomu
AU - Matsumoto, Munehiro
AU - Kimura, Hiroki
AU - Goudarzi, Houman
AU - Shimizu, Kaoruko
AU - Suzuki, Masaru
AU - Nishimura, Masaharu
AU - Konno, Satoshi
N1 - Publisher Copyright:
© 2020 Japanese Society of Allergology
PY - 2021/1
Y1 - 2021/1
N2 - Background: We recently reported that severe asthma patients with frequent exacerbations showed high blood eosinophil counts (Eo) and fractions of exhaled nitric oxide (FeNO) compared with non-exacerbators. However, we did not determine exact cutoff values related to exacerbation. The aim of this study was to determine the cutoff values of Eo and FeNO that could be related to the exacerbation of severe asthma. We also aimed to confirm the clinical utility of Th2 markers related to exacerbation. Methods: This study included 105 severe asthma patients who completed a three-year follow-up of a severe asthma cohort study, including smokers. Three Th2 markers were selected, viz., Eo, FeNO, and positive atopic status. Regarding Eo and FeNO, we determined the cutoff values for the definition of “positive” Th2 features using receiver operating characteristic curve analyses, based on the comparisons between frequent exacerbators and other patients. Results: The cutoff values for positive Th2 features were Eo ≥ 250 cells/μL and FeNO ≥31 ppb. Sixteen patients (15.2%) had no Th2 features, 40 (38.1%) had one, 25 (23.8%) had two, and 24 (22.9%) had three. A high number of positive Th2 features was significantly associated with exacerbation frequencies over three years (p < 0.05). Similarly, compared to patients with one or no Th2 features, those with three Th2 features had a significantly higher probability of having more than one exacerbation (p < 0.05). Conclusions: The cutoff values determined in the current analysis were good predictors of future exacerbations in severe asthma patients.
AB - Background: We recently reported that severe asthma patients with frequent exacerbations showed high blood eosinophil counts (Eo) and fractions of exhaled nitric oxide (FeNO) compared with non-exacerbators. However, we did not determine exact cutoff values related to exacerbation. The aim of this study was to determine the cutoff values of Eo and FeNO that could be related to the exacerbation of severe asthma. We also aimed to confirm the clinical utility of Th2 markers related to exacerbation. Methods: This study included 105 severe asthma patients who completed a three-year follow-up of a severe asthma cohort study, including smokers. Three Th2 markers were selected, viz., Eo, FeNO, and positive atopic status. Regarding Eo and FeNO, we determined the cutoff values for the definition of “positive” Th2 features using receiver operating characteristic curve analyses, based on the comparisons between frequent exacerbators and other patients. Results: The cutoff values for positive Th2 features were Eo ≥ 250 cells/μL and FeNO ≥31 ppb. Sixteen patients (15.2%) had no Th2 features, 40 (38.1%) had one, 25 (23.8%) had two, and 24 (22.9%) had three. A high number of positive Th2 features was significantly associated with exacerbation frequencies over three years (p < 0.05). Similarly, compared to patients with one or no Th2 features, those with three Th2 features had a significantly higher probability of having more than one exacerbation (p < 0.05). Conclusions: The cutoff values determined in the current analysis were good predictors of future exacerbations in severe asthma patients.
KW - Asthma
KW - Biomarkers
KW - Cutoff value
KW - Exacerbation
KW - Th2 features
UR - https://www.scopus.com/pages/publications/85091226634
UR - https://www.scopus.com/pages/publications/85091226634#tab=citedBy
U2 - 10.1016/j.alit.2020.09.001
DO - 10.1016/j.alit.2020.09.001
M3 - Article
C2 - 32952040
AN - SCOPUS:85091226634
SN - 1323-8930
VL - 70
SP - 68
EP - 73
JO - Allergology International
JF - Allergology International
IS - 1
ER -